APA (7th ed.) Citation

Iannitto, E., Ferrero, S., Bommier, C., Drandi, D., Ferrante, M., Bouabdallah, K., . . . Thieblemont, C. <i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study. Ferrata Storti Foundation.

Chicago Style (17th ed.) Citation

Iannitto, Emilio, et al. <i>Erratum</i> to: Bendamustine and Rituximab as First-line Treatment for Symptomatic Splenic Marginal Zone Lymphoma: Long-term Outcome and Impact of Early Unmeasurable Minimal Residual Disease Attainment from the BRISMA/IELSG36 Phase II Study. Ferrata Storti Foundation.

MLA (9th ed.) Citation

Iannitto, Emilio, et al. <i>Erratum</i> to: Bendamustine and Rituximab as First-line Treatment for Symptomatic Splenic Marginal Zone Lymphoma: Long-term Outcome and Impact of Early Unmeasurable Minimal Residual Disease Attainment from the BRISMA/IELSG36 Phase II Study. Ferrata Storti Foundation.